Increased patient influence when introducing new treatments and drugs in Sweden

Important results from the project

The purpose of the project is for patient and user representatives together with relevant stakeholders, to develop and achieve the goal of a collaboration model for increased patient and user influence in the HTA (Health Technology Assessment) processes involving the introduction for new treatments and drugs . Based on the challenges and results from step 1, the solution has been redefined. Our plan is still to achieve the original goal long term. In step 2 we plan to continue developing the alternative solution and focus on further analyzing and influencing structural factors.

Expected long term effects

Working to increase patient and user influence is important. Step 1 shows that patient and user representatives want to participate early in the process and the majority doesn´t believe this happens today. The long-term effect is a more needs-adapted healthcare with shorter care times, increased quality of life, less sick leave, lower production losses and less strain on relatives. Developing a collaboration model for HTA is a long-term objective. One challenge during the current pandemic has been to involve the necessary stakeholders such as authorities and decision-makers.

Approach and implementation

The project partners have performed regular work meetings. Covid-19 has contributed to a changed way of working. Physical meetings have been replaced by telephone /web interviews and two webinars. Performed activities: - Mapping of patient and user influence - External monitoring - Interviews with patient and user advocates, administrative and HTA authorities and politicians - Webinar focusing on patient and user influence with connection to Agenda 2030 - Webinar focusing on increasing the participants´ knowledge of the HTA process and present a potential HTA model for step 2.